ElevateBio Secures $401M Series D Financing, Spearheading Advancements in Cell and Gene Therapies

Waltham, MA, May 24, 2023 (Business Wire) -- ElevateBio, a leading company focused on cell and gene therapies, has successfully closed a Series D financing round, raising $401 million. The funds will fuel the expansion of ElevateBio's advanced technology platforms, including gene editing and induced pluripotent stem cells (iPSCs), and support the development of an extensive pipeline of transformative therapies.

Read full article here.